Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash & Equivalents (2023 - 2025)

Monte Rosa Therapeutics' Cash & Equivalents history spans 3 years, with the latest figure at $129.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 42.08% year-over-year to $129.9 million; the TTM value through Dec 2025 reached $129.9 million, down 42.08%, while the annual FY2025 figure was $129.9 million, 42.08% down from the prior year.
  • Cash & Equivalents reached $129.9 million in Q4 2025 per GLUE's latest filing, down from $208.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $335.1 million in Q1 2025 to a low of $47.0 million in Q2 2023.
  • Average Cash & Equivalents over 3 years is $151.6 million, with a median of $126.8 million recorded in 2023.
  • The largest YoY upside for Cash & Equivalents was 235.91% in 2025 against a maximum downside of 42.08% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $128.1 million in 2023, then skyrocketed by 75.06% to $224.3 million in 2024, then tumbled by 42.08% to $129.9 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Cash & Equivalents are $129.9 million (Q4 2025), $208.3 million (Q3 2025), and $300.9 million (Q2 2025).